A randomized phase II selection trial in patients with advanced/recurrent gastric cancer: Trial for advanced stomach cancer (TASC)

Japanese Journal of Clinical Oncology

Volumn 37, Issue 6, 2007, Pages 469-472

  Morita, Satoshi ^a   Baba, Hideo ^b   Tsuburaya, Akira ^c   Takiuchi, Hiroya ^d   Matsui, Takanori ^e   Maehara, Yoshihiko ^f   Sakamoto, Junichi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c KANAGAWA CANCER CENTER   (Japan)

^d OSAKA MEDICAL COLLEGE   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f KYUSHU UNIVERSITY   (Japan)

Author keywords

Bayesian trial monitoring; Chemotherapy; Gastric cancer; Randomized phase II trial

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; FLUOROURACIL; IRINOTECAN; PACLITAXEL;

ADVANCED CANCER; ARTICLE; BAYES THEOREM; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MONITORING; MONOTHERAPY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; STOMACH CANCER; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG COMBINATIONS; FLUOROURACIL; HUMANS; NEOPLASM RECURRENCE, LOCAL; OXONIC ACID; PACLITAXEL; STOMACH NEOPLASMS; TEGAFUR;

EID: 34547871997     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym046     Document Type: Article

References (10)

1. GLOBOCAN (2002) database http://www-dep.iarc.fr/globocan/globocan.html.
2. National Cancer Center (2005) database http://ganjoho.ncc.go.jp/ professional/statistics/statistics.html.
3. Shimada Y, Shirao K, Ohtsu A, Hyodo I, Saito H, Yamamichi N, et al. Phase III study of UFT + MMC versus 5-FU + DDP versus 5-FU alone in patients with advanced gastric cancer: JCOG study 9205. The 35th Annual Meeting of American Society of Clinical Oncology, Atlanta 1999:272a.
4. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep 1985;69:1375-81.
5. Lee JJ, Feng L. Randomized phase II designs in cancer clinical trials: current status and future directions. J Clin Oncol 2005;23:4450-7.
6. Thall PF, Sung FIG. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials. Stat Med 1998;17:1563-80.
7. Thall PF, Wooten LH, Tannir NM. Monitoring event times in early phase clinical trials: Some practical issues. Clin Trials 2005;2:467-78.
8. Spiegelhalter DJ, Freedman LS, Parmar MKB. Bayesian approaches to randomized trials. J Roy Statist Soc Ser A 1994;157:357-416.
9. Kaplan EL, Meier P. Nonparametric estimation form incomplete observations. J Am Star Assoc 1958;53:457-81.
10. Cox DR, Oakes D. Analysis of Survival Data. London: Chapman and Hall 1984.